**Patient Discharge Summary**

**Patient Information:**

* Name: John Doe
* Date of Birth: March 12, 1980
* Admission Date: March 15, 2023
* Discharge Date: March 25, 2023

**Chief Complaint:**

John Doe, a 43-year-old male, was admitted to the endocrinology unit on March 15, 2023, with complaints of increased thirst and frequent urination over the past three months.

**Medical History:**

John has no significant medical history, apart from occasional headaches and mild hypertension, which has been well-controlled with losartan 50mg once daily.

**Physical Examination:**

Upon admission, John exhibited normal vital signs, with a blood pressure of 130/80 mmHg, pulse rate of 70 beats per minute, and body mass index (BMI) of 32 kg/m2. His physical examination was otherwise normal, with no signs of acute disease.

**Laboratory Results:**

Initial laboratory tests revealed elevated fasting plasma glucose (FPG) levels of 220 mg/dL and glycosylated hemoglobin (HbA1C) of 8.2%. Oral glucose tolerance testing (OGTT) was not performed due to the patient's recent history of symptoms.

**Diagnosis and Treatment:**

Based on the laboratory results, John was diagnosed with type 2 diabetes. His treatment plan was initiated with a combination of lifestyle modifications, including a healthy diet and regular exercise, as well as medication.

**Medications:**

* Metformin 500mg twice daily, starting on March 17, 2023, to improve insulin sensitivity and reduce glucose production in the liver.
* Insulin glargine 10 units at bedtime, starting on March 20, 2023, to provide basal insulin coverage and improve glucose control.
* Liraglutide 3mg once daily, starting on March 22, 2023, as an adjunct to metformin and insulin to improve glycemic control and promote weight loss.

**Education and Counseling:**

John received detailed education on the causes of diabetes, symptoms and signs of hypoglycemia and hyperglycemia, and the importance of regular monitoring of his blood glucose levels. He was instructed on how to adjust his insulin doses based on his blood glucose levels and carbohydrate intake. He was also counseled on the importance of regular physical activity, with a minimum of 150 minutes per week, and advised to monitor his blood glucose levels before and after exercise.

**Discharge Instructions:**

John was discharged on March 25, 2023, with the following instructions:

* Continue metformin 500mg twice daily and insulin glargine 10 units at bedtime.
* Take liraglutide 3mg once daily.
* Monitor blood glucose levels at least three times a day and adjust insulin doses as necessary.
* Reduce carbohydrate intake and increase physical activity to improve glycemic control.
* Attend regular follow-up appointments with his primary care physician and endocrinologist to monitor his condition and adjust his treatment plan as needed.

**Follow-up:**

John is scheduled for a follow-up appointment with his primary care physician on April 10, 2023, and with his endocrinologist on April 25, 2023.

**Additional Recommendations:**

* John should receive regular foot examinations and podiatric care to prevent foot ulcers and complications.
* He should be vaccinated against Streptococcus pneumoniae, influenza virus, hepatitis B, varicella, and SARS-CoV-2.
* He should be encouraged to engage in regular physical activity, including both aerobic and resistance exercises, to improve glycemic control and overall health.

**Conclusion:**

John Doe was diagnosed with type 2 diabetes and was initiated on a combination therapy regimen of metformin, insulin glargine, and liraglutide. He received detailed education on his condition and was counseled on lifestyle modifications to improve glycemic control. He will require regular follow-up appointments to monitor his condition and adjust his treatment plan as needed.